Clinical trials: Intervention Phase
Hemophilia A
BAX 802 in CHA With Inhibitors
The purpose of this study is to evaluate the efficacy and safety of BAX 802 in males with congenital hemophilia A (CHA) with inhibitors who are undergoing major or minor elective surgical, dental, or other invasive procedures.
- Trial name
- CHAWI (NCT02895945)
- Testing
- Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)
- Where
- 24 sites in United States, Bulgaria and 10 more
- Volunteers
- 8 people
- Sponsor
- Baxalta now part of Shire
Idiopathic Parkinson's Disease
Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
The purpose of this study was to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.
- Trial name
- NCT01523301
- Testing
- Rotigotine
- Where
- 29 sites in South Korea
- Volunteers
- 380 people
- Sponsor
- UCB Korea Co., Ltd.
Colo-rectal Cancer
Therascreen® KRAS RGQ PCR Kit
An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples from patients with Colorectal Cancer (CRC) who have previously tested positive for the KRAS G12C mutation for…
- Trial name
- NCT05347745
- Testing
- therascreen® KRAS RGQ PCR Kit
- Where
- United Kingdom
- Volunteers
- 219 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Postoperative Nausea and Vomiting
A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)
This study will evaluate single IV doses of Vestipitant (GW597599) compared to 4 mg IV ondansetron for treating breakthrough postoperative nausea and vomiting (PONV) after failure of PONV prophylaxis with a regimen that includes…
- Trial name
- NCT01507194
- Testing
- Ondansetron, Vestipitant
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- Accenture
Coronary Artery Disease
Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation
This is an open-label, randomized, multicenter Phase II clinical study designed to evaluate the cardioprotective effect, to determine the optimal dosages and duration of inhalation, and to assess the clinical safety of the…
- Trial name
- NCT07397351
- Testing
- Aroxxen
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- Research Institute of Geroprotective Technologies
End Stage Renal Disease, Thrombosis
Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis
This study evaluates the safety and efficacy of AB002 (E-WE thrombin) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts.
- Trial name
- NCT03963895
- Testing
- AB002 Dose 1, AB002 Dose 2
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Aronora, Inc.
Atopic Dermatitis
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07220577
- Testing
- GIA632
- Where
- 28 sites in United States, Bulgaria and 7 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal…
- Trial name
- NCT04949256
- Testing
- Pembrolizumab, Lenvatinib, Cisplatin
- Where
- 198 sites in United States, Argentina and 23 more
- Volunteers
- 863 people
- Sponsor
- Merck Sharp & Dohme LLC
Androgenetic Alopecia
A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia
This is a multicentre, open label, randomized, pilot study to evaluate safety and efficacy of Human Platelet Lysate (HPL) in subjects with Androgenetic Alopecia. The study is being conducted at 2 centers in India.
- Trial name
- NCT01643629
- Testing
- Autologous Human Platelet Lysate (HPL), 2 % Minoxidil and /or Finasteride
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Kasiak Research Pvt. Ltd.
Thrombocytopenia Related to Chronic Liver Disease
Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
The purpose of this study is to evaluate the efficacy of once-daily Oral avatrombopagin subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures, to evaluate the safety of…
- Trial name
- NCT00914927
- Testing
- Avatrombopag
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Eisai Inc.
Hypotension
Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting
This is a national, multicentre, prospective, open, two-arm, non-interventional study with hospitalized patients, who are treated routinely with cafedrine/theodrenaline or ephedrine after occurrence of perioperative hypotension…
- Trial name
- NCT02893241
- Testing
- Cafedrine/theodrenaline, Ephedrine
- Where
- 75 sites in Germany
- Volunteers
- 2,013 people
- Sponsor
- Ratiopharm GmbH
Anterior Myocardial Infarction
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
The research study is being done to see if SGC001 can be used to treat people scheduled to undergo percutaneous coronary intervention for Anterior ST-segment Elevation Myocardial Infarction.
- Trial name
- NCT07091929
- Testing
- SGC001
- Where
- 4 sites in China
- Volunteers
- 38 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
Hemophilia A
Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
The purpose of the study is to evaluate the efficacy and safety of BAX 855 in severe hemophilia A previously treated (PTP) males, 12 to 65 years of age who are undergoing elective surgical or other invasive procedures.
- Trial name
- NCT01913405
- Testing
- PEGylated Recombinant factor VIII (rFVIII)
- Where
- 22 sites in United States, Bulgaria and 7 more
- Volunteers
- 30 people
- Sponsor
- Baxalta now part of Shire
Dermatitis, Atopic
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy of Bermekimab, compared with placebo, in participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04990440
- Testing
- Bermekimab
- Where
- 11 sites in United States, Argentina
- Volunteers
- 6 people
- Sponsor
- Janssen Research & Development, LLC
Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
This is a multi-center, non-interventional, study with the aim to access routine practice of diagnostic and treatment approaches in patients with NSCLC and SCLC in 50 largest oncology centers in Russian Federation.
- Trial name
- PASSAT (NCT05887011)
- Where
- 37 sites in Russia
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Sedation and Anesthesia for Adult Colonoscopy Procedures
A Study Evaluating the Efficacy and Safety of HSK3486
A double-blind, randomized, active controlled, multi-center, parallel group study comparing HSK3486 with Propofol, in patients undergoing a colonoscopy.
- Trial name
- NCT03709056
- Testing
- HSK3486, Propofol
- Where
- 8 sites in China
- Volunteers
- 94 people
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Multiple Sclerosis, CAR T Cell Therapy
MB-CART2019.1 in Refractory Multiple Sclerosis
The goal of this trial is to assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS.
- Trial name
- NCT07178431
- Testing
- MB-CART2019.1
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Miltenyi Biomedicine GmbH
Hepatitis C, Chronic
Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)
The objective of the study is to evaluate the effectiveness of PegIntron plus Rebetol combination in treating patients with chronic hepatitis C in a primary care setting.
- Trial name
- PRACTICE (NCT00709059)
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 538 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Carcinoma
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.
The Drugs Controller General of India (DCGI) granted approval for Rahika® (capmatinib) film-coated tablets (150 mg and 200 mg) for the treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT05110196
- Testing
- Capmatinib 150 mg, Capmatinib 200 mg
- Where
- 15 sites in India
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Anesthesia, General
Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
The primary purpose of the study is to determine the time-course of recovery to a T4/T1 ratio of 0.9 within 4 minutes after 4.0 mg.kg^-1 Sugammadex is administered at least 15 minutes after the last administration of rocuronium…
- Trial name
- NCT00298831
- Testing
- Sugammadex, Rocuronium
- Volunteers
- 224 people
- Sponsor
- Merck Sharp & Dohme LLC